Report error Found 2439 with Last Name = 'gilbert' and Initial = 'j'
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:Purified HDAC1-9 (0.5~5 nM) were incubated with 2 μM carboxyfluorescein (FAM)-labeled acetylated peptide substrate A or B and test compound for ...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:Purified HDAC1-9 (0.5~5 nM) were incubated with 2 μM carboxyfluorescein (FAM)-labeled acetylated peptide substrate A or B and test compound for ...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:Purified HDAC1-9 (0.5~5 nM) were incubated with 2 μM carboxyfluorescein (FAM)-labeled acetylated peptide substrate A or B and test compound for ...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:Purified HDAC1-9 (0.5~5 nM) were incubated with 2 μM carboxyfluorescein (FAM)-labeled acetylated peptide substrate A or B and test compound for ...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:Purified HDAC1-9 (0.5~5 nM) were incubated with 2 μM carboxyfluorescein (FAM)-labeled acetylated peptide substrate A or B and test compound for ...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Purified HDAC1-9 (0.5~5 nM) were incubated with 2 μM carboxyfluorescein (FAM)-labeled acetylated peptide substrate A or B and test compound for ...More data for this Ligand-Target Pair
TargetEstrogen receptor beta(Human)
University of Versailles Saint-Quentin-en-Yvelines
Curated by ChEMBL
University of Versailles Saint-Quentin-en-Yvelines
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Anti-estrogenicity for 50% inhibition of the MVLN cell luciferase activity due to 0.1 nM E2 (estradiol)More data for this Ligand-Target Pair
Affinity DataIC50: 4nMpH: 7.4 T: 2°CAssay Description:Purified HDAC1-9 (0.5~5 nM) were incubated with 2 μM carboxyfluorescein (FAM)-labeled acetylated peptide substrate A or B and test compound for ...More data for this Ligand-Target Pair
Affinity DataIC50: 11nMpH: 7.4 T: 2°CAssay Description:Purified HDAC1-9 (0.5~5 nM) were incubated with 2 μM carboxyfluorescein (FAM)-labeled acetylated peptide substrate A or B and test compound for ...More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Inhibition of BACE1 in HEK293 cells expressing APPswe/lon assessed as inhibition of amyloid beta-40 productionMore data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:In vitro inhibitory concentration against inosine-5'-monophosphate dehydrogenaseMore data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Inhibition of BACE1 in HEK293 cells expressing APPswe/lon assessed as inhibition of amyloid beta-40 productionMore data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:In vitro inhibitory concentration against inosine-5'-monophosphate dehydrogenaseMore data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:In vitro inhibitory concentration against inosine-5'-monophosphate dehydrogenaseMore data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:In vitro inhibitory concentration against inosine-5'-monophosphate dehydrogenaseMore data for this Ligand-Target Pair
Affinity DataIC50: 35nMAssay Description:Inhibitory activity against IMPDH IIMore data for this Ligand-Target Pair
Affinity DataIC50: 42nMAssay Description:Inhibition of BACE1 in HEK293 cells expressing APPswe/lon assessed as inhibition of amyloid beta-40 productionMore data for this Ligand-Target Pair
Affinity DataIC50: 45nMAssay Description:Inhibitory activity against IMPDH IIMore data for this Ligand-Target Pair
Affinity DataIC50: 47nMAssay Description:In vitro inhibitory concentration against inosine-5'-monophosphate dehydrogenaseMore data for this Ligand-Target Pair
Affinity DataIC50: 49nMAssay Description:Inhibitory activity against IMPDH IIMore data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
